Clinical Trial

Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated March 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-14; most recent amendment 2025-04-19.
Status change: Active, Not Recruiting → Recruiting 2025-04-18
Trial Details
NCT Number NCT06929507
Lead Sponsor University Hospital, Alexandroupolis
Conditions Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
Enrollment 60 participants
Start Date 2025-03-10
Primary Completion 2026-03-10 (estimated)
Study Completion 2027-03-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-24